NASDAQ:WVEWave Life Sciences Stock Price, Forecast & News

Wave Life Sciences' stock was trading at $8.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, WVE shares have increased by 25.4% and is now trading at $10.18. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Wave Life Sciences in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Wave Life Sciences.

Wave Life Sciences is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Wave Life Sciences.

Wave Life Sciences Ltd (NASDAQ:WVE) released its quarterly earnings data on Monday, May, 11th. The company reported ($1.38) EPS for the quarter, missing the Zacks' consensus estimate of ($1.34) by $0.04. The firm had revenue of $4.16 million for the quarter, compared to analysts' expectations of $7.26 million. Wave Life Sciences had a negative net margin of 1,150.43% and a negative return on equity of 219.06%. View Wave Life Sciences' earnings history.

6 brokers have issued 1 year target prices for Wave Life Sciences' shares. Their forecasts range from $10.00 to $65.00. On average, they anticipate Wave Life Sciences' share price to reach $28.00 in the next twelve months. This suggests a possible upside of 175.0% from the stock's current price. View analysts' price targets for Wave Life Sciences.

Media coverage about WVE stock has been trending somewhat positive this week, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Wave Life Sciences earned a coverage optimism score of 1.5 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutWave Life Sciences.

Wave Life Sciences saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 4,980,000 shares, an increase of 9.7% from the April 30th total of 4,540,000 shares. Based on an average trading volume of 620,800 shares, the days-to-cover ratio is currently 8.0 days. Currently, 17.6% of the company's shares are sold short. View Wave Life Sciences' Current Options Chain.

Some companies that are related to Wave Life Sciences include Constellation Pharmaceuticals (CNST), Portola Pharmaceuticals (PTLA), Intra-Cellular Therapies (ITCI), Phoenix Tree (IMAB), Karyopharm Therapeutics (KPTI), ZEALAND PHARMA/S (ZEAL), Tricida (TCDA), Arcus Biosciences (RCUS), Supernus Pharmaceuticals (SUPN), Cytokinetics (CYTK), Revance Therapeutics (RVNC), Phathom Pharmaceuticals (PHAT), Mersana Therapeutics (MRSN), Kiniksa Pharmaceuticals (KNSA) and I-Mab (ARQT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Wave Life Sciences investors own include Gilead Sciences (GILD), Crispr Therapeutics (CRSP), Exelixis (EXEL), Novavax (NVAX), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Aduro BioTech (ADRO), Micron Technology (MU), AT&T (T) and TherapeuticsMD (TXMD).

Wave Life Sciences trades on the NASDAQ under the ticker symbol "WVE."

Wave Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (8.74%), Redmile Group LLC (8.39%), BlackRock Inc. (5.25%), Primecap Management Co. CA (3.56%), JPMorgan Chase & Co. (2.25%) and Morgan Stanley (1.96%). Company insiders that own Wave Life Sciences stock include Chandra Vargeese, Chris Francis, Gregory L Verdine, Keith Regnante, Michael A Panzara, Paul Bolno and Ra Capital Management, Llc. View institutional ownership trends for Wave Life Sciences.

WVE stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Wellington Management Group LLP, Primecap Management Co. CA, Burrage Capital Management LLC, Spark Investment Management LLC, Parametric Portfolio Associates LLC, BlackRock Inc., and WS Management Lllp. Company insiders that have sold Wave Life Sciences company stock in the last year include Chandra Vargeese, Gregory L Verdine, Michael A Panzara, and Paul Bolno. View insider buying and selling activity for Wave Life Sciences.

WVE stock was purchased by a variety of institutional investors in the last quarter, including Morgan Stanley, Morgan Stanley, JPMorgan Chase & Co., Pictet Asset Management Ltd., Voloridge Investment Management LLC, Russell Investments Group Ltd., Nuveen Asset Management LLC, and Tekla Capital Management LLC. View insider buying and selling activity for Wave Life Sciences.

Shares of WVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of WVE stock can currently be purchased for approximately $10.18.

Wave Life Sciences has a market capitalization of $355.18 million and generates $15.98 million in revenue each year. The company earns $-193,640,000.00 in net income (profit) each year or ($5.72) on an earnings per share basis. Wave Life Sciences employs 250 workers across the globe.

The official website for Wave Life Sciences is www.wavelifesciences.com.

Wave Life Sciences' mailing address is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. The company can be reached via phone at 65-6236-3388 or via email at [email protected]